
Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown
Published: March 26, 2025
Language: Английский
Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown
Published: March 26, 2025
Language: Английский
International Journal of Nanomedicine, Journal Year: 2025, Volume and Issue: Volume 20, P. 871 - 886
Published: Jan. 1, 2025
This study focuses on the development and evaluation of nanostructured lipid carriers (NLCs) loaded with aloperine as a potential therapeutic approach for treatment pulmonary arterial hypertension. The NLCs were designed to enhance solubility, stability, bioavailability aloperine, compound vasodilatory anti-inflammatory properties. Through series experiments including single-factor experimentation, transmission electron microscopy, high-performance liquid chromatography, in vivo pharmacokinetics, tissue distribution studies, we assessed physicochemical properties, drug release profiles, vitro performance this novel nanocarrier. prepared aloperine-loaded exhibited milky white translucent suspension appearance, presenting quasi-spherical shape under microscope, an average particle size (509.48±30.04) nm entrapment efficiency (64.18±1.14)%. profile demonstrated good sustained-release characteristics vitro, formulation remained stable up 15 days when stored at 4°C. Compared solution group, t1/2, AUC(0→t), AUC(0→∞), MRT(0→t), clearance rate 2.3, 2.96, 3.06, 3.03, 0.22 times higher, respectively. indicates that formulating into can prolong its circulation time body. Furthermore, concentrations lungs group 1.79, 3.78, 2.30 higher than those three points (0.25 h, 1.5 4 h), suggesting increase accumulation lungs. Our findings suggest could offer promising strategy
Language: Английский
Citations
0Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown
Published: March 26, 2025
Language: Английский
Citations
0